Alopecia Areata clinical trial for adolescent age 6-18, evaluating the safety and efficacy of Baricitinib.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
More information about the Continue reading